This workshop will explore the latest advances in alpha, beta, and Auger emitters for targeted radiopharmaceutical therapy, highlighting isotopes such as actinium-225, lead-212, lutetium-177, terbium-161, radium-223, and iodine-125. Join your peers to examine how their unique radiation properties – range, energy, and DNA damage – can be leveraged to maximize tumor cell killing while minimizing salivary gland and kidney toxicity. Join this session to discover emerging isotopes that could expand the reach of radioligand therapy and enable treatment of tumors previously considered difficult or heterogeneous.

Discussion Points:

• Are you trying to get a bystander effect? If so, what isotope is best to choose to improve overall therapeutic efficacy?
• Alpha VS Beta emitters – Why move towards Alpha emitters when Beta emitters are more established?
• Why pick particular isotopes for particular targets? How to optimize this match for maximized on-target delivery and minimized off-target effects?
• Considering matching time on target with your isotope – how long before you deposit your dose?
• Considering daughter products that might emerge after initial isotope breakdown?